CATALYST PHARMACEUTICALS, INC. (CPRX) Stock
CPRX has an Alpha Score of 51 out of 100 (weak), computed on Nov 6, 2026 from 2 of 4 sub-scores. Its trailing P/E ratio is 17.4 and its net margin 37.1% (key statistics as of Nov 9, 2026).
What is CPRX's Alpha Score?
How it works →Alpha Score of 51 reflects moderate overall profile with moderate value, strong quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
What are CPRX's key statistics?
Key statistics as of Nov 9, 2026
How does CPRX's valuation compare with the Healthcare sector?
| Metric | CPRX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 17.4 | 28.8 | 113 |
| Net margin | 37.08% | 3.66% | 170 |
| Return on equity | 23.65% | 3.71% | 194 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
CPRX price chart
Powered by TradingViewWhat does CATALYST PHARMACEUTICALS, INC. do?
Catalyst Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, particularly in neuromuscular, neurological, and metabolic areas. Its primary products include FIRDAPSE (amifampridine phosphate), approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS); AGAMREE (vamorolone), a corticosteroid for Duchenne muscular dystrophy; and FYCOMPA (perampanel), used for focal onset seizures and tonic-clonic seizures. The company emphasizes patient accessibility through comprehensive support services, patient advocacy, and community-building initiatives to ensure seamless treatment access. Catalyst Pharmaceuticals Inc. maintains a strong U.S. commercial presence while pursuing strategic partnerships for global expansion. Guided by core values of passion, trust, and integrity, it prioritizes ethical standards and innovative therapies addressing unmet needs in small patient populations. Founded and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals Inc. plays a vital role in the rare disease sector by delivering targeted treatments that improve patient outcomes.